BackCancer Genetics Overview

Cancer Genetics Accounts Payable

Cancer Genetics's accounts payable is $2.3M.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$2.33M

Peer average / median

Loading

Cancer Genetics Accounts Payable History

Loading

Cancer Genetics vs. peers: Accounts Payable Comparison

Loading

Cancer Genetics Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Cancer Genetics (CGIX) FAQ

As of the most recent data (December 2020), CGIX shows a accounts payable of $2.3M. Scroll down for historical charts and peer comparison views.

Tracking CGIX's accounts payable over time shows whether Cancer Genetics is scaling, shrinking, or reshaping that part of the business. The current reading is $2.3M Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Cancer Genetics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $2.3M) with ownership activity and broader fundamentals.

Cancer Genetics's accounts payable is $2.3M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.